Dostarlimab with chemo and radiation for advanced womb cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You understand the study and sign consent before any study tests or treatment.
- Your endometrial cancer has been surgically staged (womb removed and lymph nodes checked) and confirmed as stage IIIC.
- You start treatment soon after surgery (enrolled within 8 weeks and first treatment within 10 weeks).
- You’re 18 or older, and your day-to-day functioning is good (ECOG 0–1).
- Recent blood tests are strong enough (hemoglobin, platelets, and neutrophils meet limits).
- Your kidneys, liver, and blood clotting tests are within allowed ranges, and you can wait at least a few weeks after surgery/radiation/chemo before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
This trial tests the drug dostarlimab, alone or with other therapies, given before surgery in people with advanced stage 3 or 4 endometrial cancer. The goal is to see if these treatments shrink the cancer and improve outcomes before the planned operation.
This trial tests a new drug, cadonilimab (AK104), combined with chemotherapy for women with advanced or recurrent endometrial cancer. The goal is to see if the combination can help shrink or control the cancer.
This trial compares chemotherapy alone with chemotherapy plus radiation after surgery for endometrial cancer. It is specifically for tumors that have a p53 mutation, to see which treatment helps prevent the cancer from coming back or progressing.
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.